Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Successful chemo-endocrine therapy for multiple bone metastases and myelophthisis caused by occult breast carcinoma (2000)
    Springer
    International journal of clinical oncology 5 (2000), S. 399-404 
    Details
    ISSN: 1437-7772
    Keywords: Key words Occult breast carcinoma ; Metastatic breast carcinoma ; Chemotherapy ; Endocrine therapy ; Complete response
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We report a 55-year-old postmenopausal woman with occult breast carcinoma with multiple bone metastases and myelophthisis in whom complete response (CR) was achieved with chemo-endocrine therapy. At the time of admission, she had anemia and left axillary lymph node enlargement, with extremely high levels of serum tumor markers and no breast mass on physical examination or on a mammogram. Roentgenograms and bone scintigrams showed multiple bone, lung, and pleural metastases. Bone marrow biopsy and aspiration cytology from the left axillary lymph node revealed an invasion of adenocarcinoma cells. On immunohistochemical staining, the cancer cells were positive for estrogen receptor (ER), progesterone receptor (PgR), and gross cystic disease fluid protein-15 (GCDFP-15). CR was induced with a combination chemotherapy of doxorubicin, cyclophosphamide, and 5-fluorouracil (CAF), and has been maintained with sequential docetaxel administration with endocrine therapy. Her performance status (Eastern Cooperative Oncology Group) improved from 4 to 0. This patient represents a very specific and rare case in whom a primary tumor could not be detected despite severe advanced breast carcinoma, and in whom CR was achieved by chemo-endocrine therapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/PL00012070
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Expression of apoptosis-related proteins (p53, p21WAF1, bcl-2, and bax) and sensitivity to chemotherapy in squamous cell carcinoma of the esophagus (2000)
    Springer
    International journal of clinical oncology 5 (2000), S. 89-96 
    Details
    ISSN: 1437-7772
    Keywords: Key words Esophageal carcinoma ; Chemotherapy ; p53 ; p21 ; bcl-2 ; bax
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background. Chemotherapy is an important component of the multimodal approach to the treatment of advanced esophageal squamous cell carcinoma. Methods. We investigated the associations between p53, p21 (Waf1), bcl-2, and bax expression and response to chemotherapy (cisplatin + 5-fluorouracil + leucovorin) in 43 patients with advanced esophageal squamous cell carcinoma. The expression of p53, p21 (Waf1), bcl-2, and bax proteins was analyzed immunohistologically in pretreatment biopsy and post-treatment resected specimens. Results. The 23 patients who had objective evidence of either a complete response (CR) or a partial response (PR) to chemotherapy survived for significantly longer than the 20 patients who had no response (NR). The expression of p53, p21 (Waf1), bcl-2, and bax was detected in 26 (61%), 12 (28%), 6 (14%), and 19 (44%) of the pretreatment biopsy specimens, respectively. The response to chemotherapy was not independently associated with the expression of any of these proteins. However, in the 26 patients with p53-expressing tumors, the response rate was 80% in patients whose tumor also expressed p21, whereas it was 19% in those whose tumor did not coexpress p21. No change in p53 expression was observed before and after chemotherapy, except in 1 patient; however, p21 expression appeared to be induced by chemotherapy in 5 patients. Patient survival was also not independently associated with the expression of any of these proteins. However, patients with p53-negative or p21-positive tumors had a better response to chemotherapy and survived for longer than those with p53-positive and p21-negative tumors. Conclusion. p53 and p21 expression in biopsy specimens obtained before chemotherapy could be useful predictors of response and survival in patients with advanced esophageal squamous cell carcinoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s101470050097
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age (2000)
    Springer
    Cancer chemotherapy and pharmacology 46 (2000), S. 114-118 
    Details
    ISSN: 1432-0843
    Keywords: Key words Paclitaxel ; Non-small-cell lung cancer ; Elderly ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger group) who were enrolled in two phase II trials of 3-h infusions of paclitaxel. Results: A total of 120 patients were eligible for the studies, of whom 28 were in the elderly group and 92 in the younger group. Neutropenia was the most prominent toxicity. Grade 3–4 neutropenia was recorded in 89.3% of the elderly group and in 73.9% of the younger group (P=0.13). Other hematological and non-hematological toxicities were mild regardless of age. Tumor response (46.4% vs 32.2%) and median survival time (9.8 months vs 6.8 months) did not differ between the elderly and younger groups. Pharmacokinetic studies failed to detect any difference between the two groups. Conclusion: Intravenous 3-h infusions of paclitaxel are as safe and effective in elderly patients with NSCLC as in younger patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800000143
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...